Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 6/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.49 |
| ▸ | CLK4 | Q9HAZ1 | 6/20 | 0.49 |
| ▸ | USP2 | O75604 | 5/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | GBA1 | P04062 | 1/20 | 0.47 |
| ▸ | CDK4 | P11802 | 1/20 | 0.47 |
| ▸ | CCND1 | P24385 | 1/20 | 0.47 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | SNCA | P37840 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2239858 | 0.93 | HPGD (0.57) | CYP1A2CYP3A4CYP2D6CYP2C19CLK4 | |
| SCHEMBL3962080 | 0.90 | CDK4 (0.58) | CYP1A2CYP3A4CYP2D6CYP2C19CLK4 | |
| SCHEMBL2237840 | 0.90 | CYP1A2 (0.49) | CYP1A2CYP3A4CYP2D6CYP2C19CLK4 | |
| SCHEMBL2241055 | 0.90 | CYP3A4 (0.51) | CYP1A2CYP3A4CYP2D6CYP2C19CLK4 | |
| SCHEMBL2245545 | 0.90 | CDK4 (0.49) | CYP1A2CYP3A4CYP2D6CYP2C19CLK4 | |
| SCHEMBL2237989 | 0.87 | CYP1A2 (0.63) | CYP1A2CYP3A4CYP2D6CYP2C19CLK4 | |
| SCHEMBL2237986 | 0.84 | CYP1A2 (0.55) | CYP1A2CYP3A4CYP2D6CYP2C19CLK4 | |
| SCHEMBL2241071 | 0.84 | CYP3A4 (0.57) | CYP1A2CYP3A4CYP2D6CYP2C19CLK4 | |
| SCHEMBL2244808 | 0.84 | SPR (0.59) | CYP1A2CYP3A4CYP2D6CYP2C19CLK4 | |
| SCHEMBL2245206 | 0.84 | CYP1A2 (0.55) | CYP1A2CYP3A4CYP2D6CYP2C19CLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044056-B1 | PYRIMIDINE DERIVATIVES AS ALK-5 INHIBITORS | NOVARTIS AG (CH) | 2012-08-22 | — | — | EP | claimed |
| US-20090209539-A1 | Pyrimidine derivatives as alk-5 Inhibitors | NOVARTIS AG (CH) | 2009-08-20 | — | — | US | claimed |
| EP-2044056-B1 | PYRIMIDINE DERIVATIVES AS ALK-5 INHIBITORS | NOVARTIS AG (CH) | 2012-08-22 | — | — | EP | disclosed |
| US-7989458-B2 | Pyrimidine derivatives as alk-5 inhibitors | NOVARTIS AG (CH) | 2011-08-02 | — | — | US | disclosed |
| US-20090209539-A1 | Pyrimidine derivatives as alk-5 Inhibitors | NOVARTIS AG (CH) | 2009-08-20 | — | — | US | disclosed |
| EP-2044056-A1 | PYRIMIDINE DERIVATIVES AS ALK-5 INHIBITORS | Novartis Ag (CH) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008006583-A1 | PYRIMIDINE DERIVATIVES AS ALK-5 INHIBITORS | NOVARTIS AG (CH) | 2008-01-17 | — | — | WO | disclosed |
| EP-1878733-A1 | Pyrimidine derivatives as ALK-5 inhibitors | Novartis AG (CH) | 2008-01-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209539-A1 | Pyrimidine derivatives as alk-5 Inhibitors | ALK, ACVR1, MUSK | CYP1A2 929/4885CYP3A4 1519/4885CYP2D6 1237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.